The DS8201-A-J101 study showed that in patients with advanced breast cancer having low HER-2 expression, T-DXd treatment resulted in an ORR of 37.0% and an mPFS of 11.1 months after a median of 7.5 lines of previous treatment. Here, ERBB2 is linked to breast cancer.